The Bioavailability of a Spray Dried Dispersion Solid Dose Formulation of PF-06260414 Relative to a Suspension Formulation

Pfizer

Overview

The current study will investigate the relative bioavailability of a spray dried dispersion solid dose formulation of PF 06260414 administered as a single oral dose of 30 mg of PF 06260414 relative to a single oral dose of 30 mg of PF 06260414 administered as a nanosuspension under fasted or fed conditions in healthy adult subjects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Conditions

Healthy

Interventions

PF 06260414 solid dose formulationDRUG

Single dose of 30 mg PF-06260414 given under fed/fasted conditions

PF-06260414 nanosuspensionDRUG

Single dose of 30 mg PF-06260414 given under fasted conditions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy male and/or female subjects of non childbearing potential between the ages of 18 and 55 years, inclusive. Exclusion Criteria: * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease * Any condition possibly affecting drug absorption (eg, gastrectomy)

Locations (1)

Pfizer New Haven Clinical Research Unit

New Haven, Connecticut, United States